| Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis (NCT04287608) | Regeneron Pharmaceuticals | 2021-03-10 |
| Improving the Follow up Rate for Pediatric Patients (NCT04837534) | Seva Foundation | 2021-02-15 |
| Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis (NCT04709575) | Regeneron Pharmaceuticals | 2021-01-14 |
| Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic (NCT04374656) | Johns Hopkins University | 2020-05-18 |
| A Study to Assess the Virus RNA, and miRNA Levels Related to Viral Infection, and Inflammatory Response in Tears of Patients Affected by COVID-19 Disease (NCT04346160) | G. d'Annunzio University | 2020-04-14 |
| Feasibility Study and Preliminary Application Study on Iris OCTA (NCT03631108) | Shanghai Eye Disease Prevention and Treatment Center | 2018-10-01 |
| Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects (NCT03519516) | Laboratorios Sophia S.A de C.V. | 2018-01-25 |
| Efficacy and Safety of Grass-SPIRE Registration Study (NCT02795273) | Circassia Limited | 2016-05-01 |
| Perforated Punctal Plugs for Treatment of Papillary Conjunctivitis in Otherwise Healthy Patients (NCT02503956) | Rabin Medical Center | 2015-08-01 |
| Reducing Adenoviral Patient Infected Days (NCT02472223) | Washington University School of Medicine | 2015-03-23 |
| Ocular Manifestations in Rheumatic Diseases (NCT03753893) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2013-05-01 |
| Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus (NCT01600365) | Adapt Produtos Oftalmológicos Ltda. | 2012-05-01 |
| A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067) (NCT01385371) | ALK-Abelló A/S | 2011-06-01 |
| Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081) (NCT00978029) | ALK-Abelló A/S | 2009-11-01 |
| Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis (NCT01028027) | Bausch & Lomb Incorporated | 2009-10-01 |
| Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED) (NCT00783198) | ALK-Abelló A/S | 2009-09-01 |
| Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234) (NCT00770315) | ALK-Abelló A/S | 2009-09-01 |
| A Comparison of the RPS Adeno Detector IV to Viral Cell Culture at Detecting Adenoviral Conjunctivitis (NCT00921895) | Rapid Pathogen Screening | 2009-06-01 |
| Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients (NCT00857779) | ALK-Abelló A/S | 2009-02-01 |
| Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis (NCT00732446) | Federal University of São Paulo | 2008-08-01 |
| Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis (NCT00705159) | Bausch & Lomb Incorporated | 2008-06-01 |
| Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) (NCT00550550) | ALK-Abelló A/S | 2007-11-01 |
| Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) (NCT00562159) | ALK-Abelló A/S | 2007-11-01 |
| Moxifloxacin vs. Polytrim for Conjunctivitis (NCT00581542) | University of Rochester | 2007-03-01 |
| Eye Drop Use in Glaucoma Patients Through Patient Surveys and Video Observations (NCT00522600) | Robin, Alan L., M.D. | 2007-02-01 |
| Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis (NCT00567918) | Astellas Pharma Inc | 2004-05-01 |
| Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis (NCT00567762) | Astellas Pharma Inc | 2004-02-01 |
| Evaluation and Treatment of Patients With Corneal and External Diseases (NCT00008541) | National Eye Institute (NEI) | 2001-01-02 |
| Screening for NEI Clinical Studies (NCT00001734) | National Eye Institute (NEI) | 1998-03-23 |